Category Archives: Clinical Cardiology

New observational data from Wuhan, China, suggest that hypertensive patients hospitalized with COVID-19 had a twofold increased risk of dying compared to those without hypertension, and that not being on medication for hypertension at the time of hospitalization worsens outcomes. The study also provides additional reassurance about the use of antihypertensives that target the renin-angiotensin-aldosterone system (RAAS). Patients with RAAS inhibitors were not exposed to a higher risk of mortality in our study and, after pooling previously published data in a study-level meta-analysis, the use of RAAS inhibitors was shown to be possibly associated with lower risk of mortality, write Chao Gao, MD (Xijing Hospital, Xian, China), and colleagues. Continue reading →

Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentaryon these stories, subscribe to the This Week in Cardiology podcast. For the week ending June 5, 2020, John Mandrola, MD comments on the following news and features stories Continue reading →

June 02, 2020 09:00 ET | Source: Stereotaxis, Inc. ST. Continue reading →

Canagliflozin was not found to be inferior to glimepiride, based on changes in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, for the treatment of patients with type 2 diabetes mellitus (T2DM) and stable congestive heart failure (CHF), according to study results published in ESC Heart Failure. Sodium glucose co-transporter 2 (SGLT2) inhibitors such as canagliflozin are thought to benefit patients with CHF, but little is known about the impact of these drugs on cardiac biomarkers, including NT-proBNP, in patients with T2DM and CHF. Continue reading →

Note to readers: Perry Memorial Hospital issued the following news release Friday. PRINCETON As Perry Memorial Hospital and the City of Princeton continue the due diligence process with OSF HealthCare to determine whether a transfer of ownership of the hospital will occur, learning and exchanging information about clinical care models is occurring along the way. OSF HealthCare is known for its digital health capabilities where advanced videoconferencing technology is used to connect patients to specialists who may not physically have an office in certain communities. Continue reading →

DUBLIN--(BUSINESS WIRE)--The "Companion Diagnostic Markets - the Future of Diagnostics by Funding Source and Application with Customized Forecasting/Analysis, COVID-19 Updates, and Executive and Consultant Guides 2020-2024" report has been added to ResearchAndMarkets.com's offering. Continue reading →

Written by Abantika Ghosh | New Delhi | Updated: June 6, 2020 8:53:54 am One of the two retraction statements published by the journals was from the author of the study on hydroxychloroquine on Covid-19 treatment. Continue reading →

ST. LOUIS, June 02, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it has reached a significant milestone of over 400 scientific publications now documenting the clinical benefits of Stereotaxis robotic technology. A complete, searchable database of all publications is available online at http://www.RoboticEP.com/Clinical-Data Continue reading →

Coala Life, a Swedish innovator in remote cardiac and respiratory monitoring, has launched the first smartphone powered virtual cardiac and respiratory diagnostics solution with real-time, p-wave based detection of nine common arrhythmias. The Coala is also powered by algorithms that enables physicians to remotely detect murmurs and auscultate heart and lungs during in patients daily life. Continue reading →

Adrian Hernandez was named vice dean and executive director of the Duke Clinical Research Institute last month. After a national search, the Duke University School of Medicine named Adrian Hernandez vice dean and executive director of the Duke Clinical Research Institute last month. In the new position, Hernandez oversees DCRIs research and teaching agenda, ensuring the Institute sustains a broad spectrum of clinical research programs and trials. Continue reading →